Ubs Group Ag Orchard Therapeutics PLC Transaction History

Ubs Group Ag

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.36 - $0.49 $4,692 - $6,387	13,035 Added 342.22%	16,844 $6,000
Q3 2022 Nov 10, 2022	SELL	$0.45 - $0.69 $23 - $36	-53 Reduced 1.37%	3,809 $2,000
Q2 2022 Aug 10, 2022	SELL	$0.42 - $0.78 $2,100 - $3,900	-5,000 Reduced 56.42%	3,862 $2,000
Q1 2022 May 16, 2022	SELL	$0.7 - $1.51 $6,774 - $14,613	-9,678 Reduced 52.2%	8,862 $7,000
Q4 2021 Feb 14, 2022	BUY	$1.16 - $2.23 $5,648 - $10,857	4,869 Added 35.62%	18,540 $25,000
Q3 2021 Nov 15, 2021	SELL	$2.24 - $4.29 $86,094 - $164,886	-38,435 Reduced 73.76%	13,671 $31,000
Q2 2021 Aug 13, 2021	SELL	$4.39 - $7.23 $246,801 - $406,463	-56,219 Reduced 51.9%	52,106 $229,000
Q1 2021 May 12, 2021	BUY	$4.39 - $9.08 $448,210 - $927,049	102,098 Added 1639.6%	108,325 $786,000
Q4 2020 Feb 11, 2021	BUY	$3.86 - $5.07 $9,213 - $12,102	2,387 Added 62.16%	6,227 $27,000
Q3 2020 Nov 12, 2020	BUY	$4.11 - $6.45 $69 - $109	17 Added 0.44%	3,840 $16,000
Q2 2020 Jul 31, 2020	BUY	$5.75 - $11.99 $80 - $167	14 Added 0.37%	3,823 $23,000
Q1 2020 May 01, 2020	SELL	$5.65 - $15.71 $2,090 - $5,812	-370 Reduced 8.85%	3,809 $29,000
Q4 2019 Feb 14, 2020	SELL	$10.15 - $15.58 $446 - $685	-44 Reduced 1.04%	4,179 $57,000
Q3 2019 Nov 14, 2019	BUY	$11.88 - $16.72 $2,791 - $3,929	235 Added 5.89%	4,223 $50,000
Q2 2019 Aug 14, 2019	BUY	$13.2 - $20.63 $45,724 - $71,462	3,464 Added 661.07%	3,988 $56,000
Q1 2019 May 14, 2019	SELL	$12.01 - $19.49 $8,587 - $13,935	-715 Reduced 57.71%	524 $9,000
Q4 2018 Feb 14, 2019	BUY	$12.4 - $18.7 $15,363 - $23,169	1,239 New	1,239 $19,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.